Immunochemical markers such as Ki67, morphological markers such as tumor-infiltrating lymphocytes (TIL), and genomic profile markers such as the Oncotype DX Recurrence Score have been used in studies, but there is insufficient evidence to support their use to guide clinical decisions for neoadjuvant therapy [10]. This evidence concerns the gene MKI67 and neoplasm.